You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

SUMATRIPTAN Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Sumatriptan, and when can generic versions of Sumatriptan launch?

Sumatriptan is a drug marketed by Cipla, Florida, Lannett Co Inc, Padagis Israel, Aurobindo Pharma Ltd, Rising, Sun Pharm, Antares Pharma Inc, Baxter Hlthcare Corp, Caplin, Dr Reddys, Endo Operations, Eugia Pharma, Fresenius Kabi Usa, Hikma, Norvium Bioscience, Sandoz, Steriscience, Teva Parenteral, Teva Pharms Usa, West-ward Pharms Int, Wockhardt, Zydus, Aurobindo Pharma, Corepharma, Dr Reddys Labs Inc, Fosun Pharma, Hikma Pharms, Mylan, Orbion Pharms, Roxane, Sun Pharm Inds, Sun Pharm Inds Ltd, Teva, and Watson Labs. and is included in forty-one NDAs.

The generic ingredient in SUMATRIPTAN is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Sumatriptan

A generic version of SUMATRIPTAN was approved as sumatriptan succinate by WEST-WARD PHARMS INT on February 6^th, 2009.

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for SUMATRIPTAN?
What are the global sales for SUMATRIPTAN?
What is Average Wholesale Price for SUMATRIPTAN?

Summary for SUMATRIPTAN

US Patents:	0
Applicants:	35
NDAs:	41
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	70
Clinical Trials:	115
Patent Applications:	5,668
Drug Prices:	Drug price information for SUMATRIPTAN
Drug Sales Revenues:	Drug sales revenues for SUMATRIPTAN
What excipients (inactive ingredients) are in SUMATRIPTAN?	SUMATRIPTAN excipients list
DailyMed Link:	SUMATRIPTAN at DailyMed

Drug patent expirations by year for SUMATRIPTAN

Drug Prices for SUMATRIPTAN

Recent Clinical Trials for SUMATRIPTAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Canisius-Wilhelmina Hospital	Phase 2
Leiden University Medical Center	Phase 2
ZonMw: The Netherlands Organisation for Health Research and Development	Phase 2

See all SUMATRIPTAN clinical trials

Pharmacology for SUMATRIPTAN

Drug Class	Serotonin-1b and Serotonin-1d Receptor Agonist
Mechanism of Action	Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists

Medical Subject Heading (MeSH) Categories for SUMATRIPTAN

Serotonin 5-HT1 Receptor Agonists
Vasoconstrictor Agents

Anatomical Therapeutic Chemical (ATC) Classes for SUMATRIPTAN

N02CC	Selective serotonin (5HT1) agonists
N02C	ANTIMIGRAINE PREPARATIONS
N02	ANALGESICS
N	Nervous system

US Patents and Regulatory Information for SUMATRIPTAN

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	SUMATRIPTAN SUCCINATE	sumatriptan succinate	TABLET;ORAL	076933-003	Aug 10, 2009	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Dr Reddys Labs Inc	SUMATRIPTAN SUCCINATE	sumatriptan succinate	TABLET;ORAL	076847-002	Aug 10, 2009	AB	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Wockhardt	SUMATRIPTAN SUCCINATE	sumatriptan succinate	INJECTABLE;SUBCUTANEOUS	078593-001	Feb 6, 2009	AP	RX	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Mylan	SUMATRIPTAN SUCCINATE	sumatriptan succinate	TABLET;ORAL	077163-001	Nov 2, 2009		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Roxane	SUMATRIPTAN SUCCINATE	sumatriptan succinate	TABLET;ORAL	078241-003	Aug 10, 2009		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Fosun Pharma	SUMATRIPTAN SUCCINATE	sumatriptan succinate	TABLET;ORAL	076976-003	Aug 10, 2009		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

EU/EMA Drug Approvals for SUMATRIPTAN

Subscribe to access the full database, or Sign Up
Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Galpharm Healthcare Ltd.	Sumatriptan Galpharm	sumatriptan	EMEA/H/C/002140	Refused	yes	no	no		2012-02-09
>Company	>Drugname	>Inn	>Product Number / Indication	>Status	>Generic	>Biosimilar	>Orphan	>Marketing Authorisation	>Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.